| abstract |
This invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition; a method of treating a disease mediated by an MMP-13 enzyme in a mammal; and a therapeutic combination containing at least two pharmaceutically active components, wherein R 1 , Q, W 1 , W 2 , R 2a , L 1 , and R 3 , the pharmaceutical composition, the method of treating, and the therapeutic combination are as defined in the specification. |